Inès Holzbaur is a general partner at AmorChem, a life sciences venture capital fund. In 2011, Dr. Holzbaur participated in the origination and establishment of AmorChem’s disruptive model for financing very early-stage drug development projects. As part of the fund’s activities, she led the closing of a strategic alliance with the pharmaceutical company Roche and the sale of a portfolio asset to Vertex Pharmaceuticals. Dr. Holzbaur is also the chairman of the board of NuChem Therapeutics Inc., a medicinal chemistry CRO founded by AmorChem. She began her career in 1999 as a manager and then vice-president of the GeneChem and AgeChem venture capital funds. During this period, she financed several companies in Canada, the US and Europe. As a result, she has held positions on the board of a number of companies, notable two pioneers in the field of immuno-oncology, BioVex inc., which was sold to Amgen for $1B and Argos Therapeutics Inc., which obtained a NASDAQ listing in 2014. In addition to her fund management activities, she is a member of the board of directors of Réseau Capital and of the Centre Québécois pour l’innovation en biotechnologie. Dr. Holzbaur received a bachelor’s degree in chemistry from Concordia University and a Ph.D. in chemistry from Cambridge University in the UK.
Frédéric Lemaître Auger is Senior Director, Investments at Accel-Rx, Canada’s national health sciences accelerator. Frédéric brings extensive health sciences venture capital expertise through his prior involvement with Desjardins Venture Capital and CDP Capital – Technology Venture (Sofinov) where he was involved in both biopharmaceutical and medical device deals. At Sofinov, he was involved in investments such as NuVasive, Inhibitex, IntraLuminal Therapeutics, Acurian, and TransMedics. While at Desjardins, he showed significant leadership in the creation and management of a profitable early-stage health sciences investment portfolio that included, amongst others, BioAxone Therapeutics, Enobia Pharma, and Tranzyme. In recent years, Frédéric was involved in project-based investments, as well as developing licensing and spin-off opportunities at MSBi Valorisation (now Aligo Innovation). He has served on the board of directors of many health sciences company and has been involved on organizing committees of conferences such as MedTech North and AdvaMed. Frédéric holds an MBA in Finance and International Management from HEC Montréal, a M.Sc. in Organic Chemistry and a Ph.D. in Polymer Physical Chemistry, both from Université de Montréal.
Pierre Beauparlant has more than 19 years of experience in large pharma and development stage, venture backed biopharmaceutical companies with expertise from discovery through commercialization. As Chief Executive Officer, Dr. Beauparlant is responsible for the direction and execution of the business strategy for SpecificiT Pharma.
Dr. Beauparlant most recently served as Medical Therapeutic Head – Hematology at Novartis Pharmaceuticals Canada. During his work at Novartis, Pierre oversaw 46 clinical trials and supported Drug Regulatory Affairs and Market Access departments in their submissions to regulatory authorities.
Prior to Novartis, Dr. Beauparlant held roles of increasing responsibility at Gemin X Pharmaceuticals Inc., a venture-backed clinical stage oncology company sold to Cephalon in 2011. As Vice President Research and Scientific Development, he held responsibilities for advancing drug discovery projects to identify new chemical entities for the treatment of cancer, business development, in-licensing, and intellectual property. Dr. Beauparlant is also Chief Business Officer at Therillia and CEO of PreciThera Inc. Dr. Beauparlant holds a Ph.D. from McGill University.